Table 2Summary of included studies.

StudyPopulationInterventionComparisonOutcomesComment

Chu 2020

Randomised Control Trial

UK (Multi-Centre- 28 UK hospitals)

N=711

Mifepristone plus misoprostol group: n= 357

Placebo plus misoprostol group: n= 354

Maternal age (years):

Mifepristone plus misoprostol group: 32.8 ± 5.6

Placebo plus misoprostol group: 32.7 ± 5.5

BMI (kg/m2):

Mifepristone plus misoprostol group: 25.8 ± 5.6

Placebo plus misoprostol group: 26.5 ± 5.5

200mg oral Mifepristone plus 800 micrograms vaginal, oral, or sublingual misoprostolOral placebo plus 800 micrograms vaginal, oral, or sublingual misoprostol
  • Failure to spontaneously pass the gestational sac within 7 days after random assignment.
  • Surgical intervention to complete the miscarriage up to discharge from hospital care.
  • Surgical intervention to complete the miscarriage up to and including 7 days after random assignment.
  • Surgical intervention to complete the miscarriage from after day 7 and up to discharge.
  • Need for further doses of misoprostol within 7 days after random assignment.
  • Need for further doses of misoprostol up to discharge.
  • Infection requiring outpatient antibiotic treatment.
  • Infection requiring inpatient antibiotic treatment.
  • Negative pregnancy test result 21 days (±2 days) after random assignment.
  • Duration of bleeding as reported by the participant.
  • Requirement for blood transfusion.
  • Side-effects.
  • Any serious complications.
  • Maternal death.
  • Follow up time was unclear for some outcomes
  • Details of adverse and serious adverse events were not reported

BMI: Body Mass Index

From: Medical management of miscarriage

Cover of Medical management of miscarriage
Medical management of miscarriage: Ectopic pregnancy and miscarriage: Evidence review D.
NICE Guideline, No. 126.
Copyright © NICE 2023.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.